Abstract
Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 347-357 |
| Number of pages | 11 |
| Journal | Cancer Biotherapy and Radiopharmaceuticals |
| Volume | 16 |
| Issue number | 5 |
| State | Published - 2001 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
- Oncology
Cite this
Sentinel lymph node biopsy for breast cancer. / Bold, Richard J; Schlieman, M.; Fahy, B. N.
In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 16, No. 5, 2001, p. 347-357.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sentinel lymph node biopsy for breast cancer
AU - Bold, Richard J
AU - Schlieman, M.
AU - Fahy, B. N.
PY - 2001
Y1 - 2001
N2 - Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.
AB - Sentinel lymph node biopsy (SLNB) is an emerging surgical technique to improve lymph node staging for breast cancer. Despite the rapid development of this technique, there remain aspects of SLNB that need to be further defined to provide a standardized approach. Variables, including patient selection, technical details for the performance of SLNB, extent of pathologic evaluation of the sentinel lymph node, and the impact of micrometastases, are areas of controversy. This paper reviews the controversies and discusses available data as well as personal experience and opinion.
UR - http://www.scopus.com/inward/record.url?scp=0035217908&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035217908&partnerID=8YFLogxK
M3 - Article
C2 - 11776752
AN - SCOPUS:0035217908
VL - 16
SP - 347
EP - 357
JO - Cancer Biotherapy and Radiopharmaceuticals
JF - Cancer Biotherapy and Radiopharmaceuticals
SN - 1084-9785
IS - 5
ER -